
Hedley Ca Emsley

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7242810/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The impact of smoking cessation on multiple sclerosis disease progression. Brain, 2022, 145, 1368-1378.	7.6	16
2	Immunomodulatory treatment for amyotrophic lateral sclerosis/motor neuron disease. The Cochrane Library, 2022, 2022, .	2.8	0
3	Late-onset epilepsy predicts stroke: Systematic review and meta-analysis. Epilepsy and Behavior, 2021, 115, 107634.	1.7	10
4	Rates, risks and routes to reduce vascular dementia (R4vad), a UK-wide multicentre prospective observational cohort study of cognition after stroke: Protocol. European Stroke Journal, 2021, 6, 89-101.	5.5	15
5	Illicit Drugs and Reversible Cerebral Vasoconstriction Syndrome. Neurohospitalist, The, 2021, 11, 40-44.	0.8	8
6	Glucagon-like peptide-1 receptor agonists as neuroprotective agents for ischemic stroke: a systematic scoping review. Journal of Cerebral Blood Flow and Metabolism, 2021, 41, 14-30.	4.3	25
7	Development of imaging-based risk scores for prediction of intracranial haemorrhage and ischaemic stroke in patients taking antithrombotic therapy after ischaemic stroke or transient ischaemic attack: a pooled analysis of individual patient data from cohort studies. Lancet Neurology, The, 2021, 20, 294-303.	10.2	37
8	The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. Lancet, The, 2021, 397, 1363-1374.	13.7	93
9	The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. Lancet, The, 2021, 397, 1375-1386.	13.7	104
10	International Multicenter Analysis of Brain Structure Across Clinical Stages of Parkinson's Disease. Movement Disorders, 2021, 36, 2583-2594.	3.9	54
11	Validation of ICD-10 codes shows intracranial venous thrombosis incidence to be higher than previously reported. Health Information Management Journal, 2020, 49, 58-61.	1.2	24
12	Seizures in the context of occult cerebrovascular disease. Epilepsy and Behavior, 2020, 104, 106396.	1.7	11
13	Routinely collected patient data in neurology research: a systematic mapping review. BMC Neurology, 2020, 20, 431.	1.8	6
14	GLP-1 receptor agonists for Parkinson's disease. The Cochrane Library, 2020, 2020, CD012990.	2.8	24
15	Baseline factors associated with early and late death in intracerebral haemorrhage survivors. European Journal of Neurology, 2020, 27, 1257-1263.	3.3	5
16	Stenting for symptomatic vertebral artery stenosis: a preplanned pooled individual patient data analysis. Lancet Neurology, The, 2019, 18, 666-673.	10.2	39
17	Cerebral microbleeds and stroke risk after ischaemic stroke or transient ischaemic attack: a pooled analysis of individual patient data from cohort studies. Lancet Neurology, The, 2019, 18, 653-665.	10.2	143
18	Interleukin-1 receptor antagonist treatment in acute ischaemic stroke does not alter systemic markers of anti-microbial defence. F1000Research, 2019, 8, 1039.	1.6	6

#	Article	IF	CITATIONS
19	Interleukin-1 receptor antagonist treatment in acute ischaemic stroke does not alter systemic markers of anti-microbial defence. F1000Research, 2019, 8, 1039.	1.6	5
20	Extracranial arterial wall volume is increased and shows relationships with vascular MRI measures in idiopathic Parkinson's disease. Clinical Neurology and Neurosurgery, 2018, 167, 54-58.	1.4	3
21	Cognitive Impairment Before Intracerebral Hemorrhage Is Associated With Cerebral Amyloid Angiopathy. Stroke, 2018, 49, 40-45.	2.0	39
22	Cerebral microbleeds and intracranial haemorrhage risk in patients anticoagulated for atrial fibrillation after acute ischaemic stroke or transient ischaemic attack (CROMIS-2): a multicentre observational cohort study. Lancet Neurology, The, 2018, 17, 539-547.	10.2	192
23	Structural and physiological neurovascular changes in idiopathic Parkinson's disease and its clinical phenotypes. Journal of Cerebral Blood Flow and Metabolism, 2017, 37, 3409-3421.	4.3	50
24	Reasons for non-recruitment of eligible patients to a randomised controlled trial of secondary prevention after intracerebral haemorrhage: observational study. Trials, 2017, 18, 162.	1.6	9
25	Arterial ischemic stroke in HIV. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e254.	6.0	45
26	<i>â€~It was like he was in the room with us':</i> patients' and carers' perspectives of telemedicine in acute stroke. Health Expectations, 2016, 19, 98-111.	2.6	17
27	HIV, antiretroviral treatment, hypertension, and stroke in Malawian adults. Neurology, 2016, 86, 324-333.	1.1	129
28	SIMILARITIES IN ARTERIAL ARRIVAL TIME PROLONGATION AND POSTERIOR HYPOPERFUSION IN PATIENTS WITH IDIOPATHIC PARKINSON'S DISEASE AND STROKE. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, e4.78-e4.	1.9	0
29	Structural and physiological MRI correlates of occult cerebrovascular disease in late-onset epilepsy. NeuroImage: Clinical, 2015, 9, 128-133.	2.7	26
30	Response. Clinical Medicine, 2015, 15, 212.	1.9	0
31	Myasthenia gravis as a â€~stroke mimic' – it's all in the history. Clinical Medicine, 2014, 14, 640-642.	1.9	10
32	WHITE MATTER LESIONS AFTER CEREBRAL ANEURYSM COILING. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, e4.121-e4.	1.9	0
33	Arterial spin labelling reveals prolonged arterial arrival time in idiopathic Parkinson's disease. NeuroImage: Clinical, 2014, 6, 1-8.	2.7	62
34	Late-Onset Epilepsy and Occult Cerebrovascular Disease. Journal of Cerebral Blood Flow and Metabolism, 2014, 34, 564-570.	4.3	42
35	Variations in inflammation-related genes may be associated with childhood febrile seizure susceptibility. Seizure: the Journal of the British Epilepsy Association, 2014, 23, 457-461.	2.0	16
36	The challenges of implementing a telestroke network: a systematic review and case study. BMC Medical Informatics and Decision Making, 2013, 13, 125.	3.0	26

#	Article	IF	CITATIONS
37	Prevalence and subtypes of radiological cerebrovascular disease in late-onset isolated seizures and epilepsy. Clinical Neurology and Neurosurgery, 2013, 115, 591-596.	1.4	50
38	Acute Stroke Training and Assessment in Computerised Axial Tomography (ASTRACAT) for stroke physicians: facilitating telestroke implementation in a UK setting. Journal of Contemporary Medical Education, 2013, 1, 137.	0.2	0
39	Hi4D-ADSIP 3-D dynamic facial articulation database. Image and Vision Computing, 2012, 30, 713-727.	4.5	36
40	When stopping the antiplatelet drugs stopped the â€~TIAs'. Practical Neurology, 2012, 12, 36-39.	1.1	4
41	Interleukin-1 receptor antagonist reverses stroke-associated peripheral immune suppression. Cytokine, 2012, 58, 384-389.	3.2	57
42	HIV infection and stroke: current perspectives and future directions. Lancet Neurology, The, 2012, 11, 878-890.	10.2	231
43	Calibrated fMRI during a cognitive Stroop task reveals reduced metabolic response with increasing age. NeuroImage, 2012, 59, 1143-1151.	4.2	73
44	Dermatomes and dogma. Practical Neurology, 2011, 11, 100-105.	1.1	18
45	Prevalence of radiological and clinical cerebrovascular disease in idiopathic Parkinson's disease. Clinical Neurology and Neurosurgery, 2011, 113, 830-834.	1.4	25
46	Rapidly progressive polyneuropathy due to dry beriberi in a man: a case report. Journal of Medical Case Reports, 2010, 4, 409.	0.8	14
47	Improving undergraduate clinical neurology bedside teaching: opening the magic circle. Clinical Teacher, 2009, 6, 172-176.	0.8	1
48	Inflammation in Acute Ischemic Stroke and its Relevance to Stroke Critical Care. Neurocritical Care, 2008, 9, 125-138.	2.4	87
49	Acute ischaemic stroke and infection: recent and emerging concepts. Lancet Neurology, The, 2008, 7, 341-353.	10.2	370
50	The incidence of acute encephalitis syndrome in Western industrialised and tropical countries. Virology Journal, 2008, 5, 134.	3.4	118
51	Infection and Brain-Induced Immunodepression After Acute Ischemic Stroke. Stroke, 2008, 39, e7; author reply e8.	2.0	11
52	Clinical outcome following acute ischaemic stroke relates to both activation and autoregulatory inhibition of cytokine production. BMC Neurology, 2007, 7, 5.	1.8	70
53	Variability of the systemic acute phase response after ischemic stroke. Journal of the Neurological Sciences, 2006, 251, 77-81.	0.6	62
54	Circle of Willis variation in a complex stroke presentation: a case report. BMC Neurology, 2006, 6, 13.	1.8	0

#	Article	IF	CITATIONS
55	Interleukin-6 and acute ischaemic stroke. Acta Neurologica Scandinavica, 2005, 112, 273-274.	2.1	6
56	Correlation of Systemic Inflammatory Response With Infarct Volume in Acute Ischemic Stroke Patients. Stroke, 2005, 36, 228-229.	2.0	9
57	Evaluation of C-Reactive Protein Measurement for Assessing the Risk and Prognosis in Ischemic Stroke, 2005, 36, 1316-1329.	2.0	256
58	Reliability of a Semi-Automated Technique of Cerebral Infarct Volume Measurement with CT. Cerebrovascular Diseases, 2004, 18, 220-226.	1.7	10
59	Peak plasma interleukin-6 and other peripheral markers of inflammation in the first week of ischaemic stroke correlate with brain infarct volume, stroke severity and long-term outcome. BMC Neurology, 2004, 4, 2.	1.8	389
60	An early and sustained peripheral inflammatory response in acute ischaemic stroke: relationships with infection and atherosclerosis. Journal of Neuroimmunology, 2003, 139, 93-101.	2.3	264
61	Elevated Circulating Interleukin-6 Levels in Acute Ischaemic Stroke Are Correlated with Ct Infarct Volume and Poor Clinical Outcome. Clinical Science, 2002, 103, 18P-19P.	0.0	0
62	Inflammatory demyelinating polyradiculoneuropathy associated with membranous glomerulonephritis and thrombocytopaenia. Clinical Neurology and Neurosurgery, 2002, 105, 23-26.	1.4	33
63	The Oxfordshire Community Stroke Project classification in the early hours of ischemic stroke and relation to infarct site and size on cranial computed tomography. Journal of Stroke and Cerebrovascular Diseases, 2001, 10, 205-209.	1.6	24
64	GLP-1 receptor agonists for Parkinson's disease. The Cochrane Library, 0, , .	2.8	4